Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

75%

6 trials in Phase 3/4

Results Transparency

100%

7 of 7 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 4

3(37.5%)

Phase 3

3(37.5%)

Phase 1

1(12.5%)

Phase 2

1(12.5%)

8Total

Phase 4(3)

Phase 3(3)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT00418821Phase 4Terminated

A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants

Role: collaborator

NCT00912925Phase 3Completed

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

Role: collaborator

NCT00146770Phase 3Completed

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Role: collaborator

NCT00146757Phase 2Completed

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

Role: collaborator

NCT00144781Phase 4Completed

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

Role: collaborator

NCT00741338Phase 1Completed

Immune Tolerance Study With Aldurazyme® (Laronidase)

Role: collaborator

NCT00144768Phase 4Completed

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

Role: collaborator

NCT00258011Phase 3Completed

Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease

Role: collaborator

All 8 trials loaded